Shortlisted as Best Patient-Focused Technological Development in Clinical & Research Excellence Awards (CARE) Awards
CRF Health, the leading provider of patient-centered eSource for the life sciences industry, today announced that its TrialConsent® electronic informed consent solution has been shortlisted for the ‘Best Patient-Focused Technological Development’ category in the 2018 Clinical & Research Excellence (CARE) Awards. In light of recent award successes, this honor further recognizes CRF Health for its disruptive and innovative solutions in the industry through this first-of-its-kind eConsent and eCOA hybrid technology to support and enable patient-centric clinical trials.
This year’s CARE award received a significant 53% increase in entries, the quality of which was deemed extremely high. The ‘Best Patient-Focused Technology Development’ category assesses entrants on their ability to gather high-quality patient data via digital tools, and solutions which best represent advances in improving data collection and/or the patient experience in clinical trials. TrialConsent provides an electronic solution for the development, use, oversight and archiving of informed consent. A major advancement in improving patient comprehension in clinical research, TrialConsent incorporates recommendations from the FDA’s Guidance on informed consent and the Clinical Trial Transformation Initiative’s (CTTI) recommendations for improving approaches to informed consent. This enables sponsors, Institutional Review Boards (IRB/IEC) and research sites to achieve better patient-centered trials. Featuring rich multimedia, tiered-learning and interactive learning assessments, TrialConsent improves recruitment and retention rates through better comprehension of consent materials by trial participants. It also allows for greater consistency and control in the informed consent process thereby limiting regulatory risk.
Speaking on the third award announcement this year for TrialConsent, Rachael Wyllie, CRF Health’s CEO, commented: “TrialConsent allows trial designs to easily integrate electronic informed consent and eCOA solutions on a single platform, and even on the same device. This pioneering hybrid solution removes the need for a separate consenting technology to be used, significantly reducing complexity for researchers and providing an intelligent solution which makes the informed consent process more effective and more efficiently streamlined for all stakeholders. We are delighted that TrialConsent has once again been shortlisted as a finalist in the 2018 CARE Awards.”
Winners will be announced at The CARE Awards ceremony which takes place in Boston, MA, on April 25, 2018. Attended by distinguished leaders in the biopharmaceutical, CRO and diagnostic industries from all corners of the globe, the awards celebrate achievements across the clinical research industry.